Clinical Trials
81 trialsTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
VITAL
Sanofi
SAMCO
Federation Francophone de Cancerologie Digestive
PROTECT
Centre Hospitalier Universitaire de Nice
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
FOLFA
Federation Francophone de Cancerologie Digestive
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
ELDERLY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
AIO-Studien-gGmbH
MERLIN
Novartis
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
RIA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Yonsei University
Aflibercept for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
C261
Brown University
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
DISTINCTIVE
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
PERMAD
University of Ulm
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
MINOAS
Hellenic Oncology Research Group
X-TRAP
Duke University
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Sanofi
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
MOMENTUM1
Jules Bordet Institute
AMALTHEA
Hellenic Cooperative Oncology Group
AUSCOR
Barts & The London NHS Trust
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
BOS3
European Organisation for Research and Treatment of Cancer - EORTC
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
VELVET
GERCOR - Multidisciplinary Oncology Cooperative Group
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
AFEQT
Sanofi
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
AFLAME
Sanofi
VENICE
Sanofi
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Sanofi